Presence of BRAF V600E in very early stages of papillary thyroid carcinoma

Thyroid

Volumn 17, Issue 5, 2007, Pages 381-388

  Ugolini, Clara ^a   Giannini, Riccardo ^a   Lupi, Cristiana ^a   Salvatore, Giuliana ^b,c   Miccoli, Paolo ^a   Proietti, Agnese ^a   Elisei, Rossella ^a   Santoro, Massimo ^b   Basolo, Fulvio ^a,d  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Division of Pathology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GALECTIN 3;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOLOGY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID DISEASE; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 34249940475     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.0305     Document Type: Article

References (22)

1. DeLellis RA, Williams ED 2004 Thyroid and parathyroid tumors. In: DeLellis RA et al. (eds) World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of Endocrine Organs. WHO Press, Geneva, p 51.
2. Sherman SI 2003 Thyroid carcinoma. Lancet 361:501-511.
3. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
4. Topliss D 2004 Thyroid incidentaloma: the ignorant in pursuit of the impalpable. Clin Endocrinol (Oxf) 60:18-20.
5. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, Shong YK 2004 Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 60:21-28.
6. Barbara D, Simi U, Meucci G, Lapi P, Orsini P, Pasquini C 2005 Thyroid papillary cancers: microcarcinoma and carcinoma, incidental cancers and non-incidental cancers - are they different diseases? Clin Endocrinol (Oxf) 63:577-581.
7. Miccoli P, Minuto MN, Galleri D, D'Agostino J, Basolo F, Antonangeli L, Aghini-Lombardi F, Berti P 2006 Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg 76:123-126.
8. Kim KH, Suh KS, Kang DW, Kang DY 2005 Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 55:540-545.
9. Garnett MJ, Marais R 2004 Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6:313-319.
10. Xing M 2005 BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262.
11. Kondo T, Ezzat S, Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306.
12. Groussin L, Fagin JA 2006 Significance of BRAF mutations in papillary thyroid carcinoma; prognostic and therapeutic implications. Nat Clin Pract Endocrinol Metab 2:180-181.
13. Trovisco V, Soares P, Preto A, Vieira de Castro I, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, Magalhaes J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simoes M 2005Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virch Arch 446:589-595.
14. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, Beck-Peccoz P 2004 BRAF mutations in an Italian cohort of thyroid cancers. Clin Endoc 61:239-243.
15. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379.
16. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
17. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA 2005 Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65:4238-4245.
18. Knauf JA, Ouyang B, Knudsen ES, Fukasawa K, Babcock G, Fagin JA 2006 Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J Biol Chem 281:3800-3809.
19. - targeting to the membrane. Endocr Relat Cancer 13:257-269.
20. Hedinger C, Williams ED, Sobin LH 1989 The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63:908-911.
21. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M 2005 The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068-1081.
22. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C Jr, Knauf JA, Zhang L, Taira K, Fagin JA 2006 BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Endocrinology 147:1014-1019.